Kymera Therapeutics Inc (KYMR) Stock Price, Quote & News

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 5300

Website: www.kymeratx.com

Address:

500 North Beacon Street, 4th Floor, Watertown, United States

d_risk Aug. 12 at 1:01 AM

$KYMR - Kymera Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors Kymera’s latest 10-Q flags its unproven business model, ongoing losses, heavy reliance on novel TPD tech, clinical and manufacturing hurdles, market and regulatory volatility, liquidity risks, and expanded threats from financial, legal, and operational disruptions—despite a strong cash runway into 2028. #Biotechnology #LiquidityRisk #RegulatoryVolatility #ClinicalRisk #TargetedProteinDegradation 🟢 Added 🟠 Removed https://d-risk.ai/KYMR/10-Q/2025-08-11

0 · Reply

OpenOutcrier Aug. 11 at 12:59 PM

$KYMR (-6.5% pre) Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update https://ooc.bz/l/73463

0 · Reply

mikesterz7 Aug. 11 at 11:37 AM

$KYMR Kymera reported second quarter EPS of $-0.95, $0.12 worse than the analyst estimate of $-0.83. Revenue for the quarter came in at $11.48M versus the consensus estimate of $20M.

1 · Reply

justiceforb_85 Aug. 7 at 10:27 PM

$KYMR trying to understand why KT-474 development discontinued when that's where they presented good preliminary data? Why do they think KT-485 is superior?

0 · Reply

BioTechHealthX Aug. 6 at 4:39 PM

$KYMR With KT-621 showing Dupixent-like results and a pipeline full of first-in-class therapies, Kymera could be the biotech dream stock. https://biotechhealthx.com/biotech-news/2-3-billion-potential-why-kymera-therapeutics-kymr-might-be-the-biggest-sleeper-stock-in-biotech/

0 · Reply

Tumble51 Aug. 6 at 1:08 PM

$CADL Tells you something $KYMR has nothing to do, BUT is at $44 TAK is without credibility…clearly ! Under valued , no !

0 · Reply

Tumble51 Jul. 25 at 1:40 PM

$CADL Wall Street thinks more of $KYMR with NO PHASE 1 completed than they do of TAK , hahahaha $45 …no phase 1, done ..no ph2 or ph3 Read the truth and weep

1 · Reply

ZacksResearch Jul. 18 at 6:03 PM

$KYMR surges 70.7% — what's fueling the rally? 🚀 Kymera's collaboration with $GILD on a novel CDK2-targeting drug has impressed investors, potentially offering more precise cancer treatments. The deal brings an $85M upfront payment and up to $750M in future payments. 💰 Despite a setback in its Sanofi deal, KYMR has outperformed the industry, sector, and S&P 500. See why KYMR could be a hidden gem in biotech 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-body-2543&ADID=SYND_STOCKTWITS_TWEET_2_2591761_BODY_2543

0 · Reply

dka79 Jul. 18 at 5:22 PM

$KYMR blackrock is 5% share holder now check filing

0 · Reply

ZacksResearch Jul. 18 at 1:08 PM

$KYMR up 70% in 3 months — still room to run or time to lock in gains? The $750M GILD oncology deal plus pipeline traction in targeted protein degradation (TPD) have powered the surge. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-teaser-2516&ADID=SYND_STOCKTWITS_TWEET_2_2591761_TEASER_2516

1 · Reply

The Best Small-Cap Stocks to Buy Now

DNLI WAY

Aug 11, 2025, 1:25 PM EDT - 12 days ago

Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 13 days ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Jun 26, 2025, 11:56 PM EDT - 2 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Jun 25, 2025, 4:05 PM EDT - 2 months ago

Kymera Therapeutics Announces Proposed Public Offering

Jun 25, 2025, 9:15 AM EDT - 2 months ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

GILD

Jun 25, 2025, 7:05 AM EDT - 2 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:00 AM EDT - 2 months ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

GILD

Jun 5, 2025, 4:16 PM EDT - 2 months ago

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Jun 2, 2025, 2:55 PM EDT - 2 months ago

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Jun 2, 2025, 7:44 AM EDT - 2 months ago

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

May 30, 2025, 4:01 PM EDT - 3 months ago

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

May 29, 2025, 7:00 AM EDT - 3 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

May 19, 2025, 12:15 PM EDT - 3 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

May 14, 2025, 4:59 PM EDT - 3 months ago

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

May 9, 2025, 9:37 PM EDT - 3 months ago

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:01 AM EDT - 3 months ago

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

May 9, 2025, 7:00 AM EDT - 3 months ago

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

May 7, 2025, 7:00 AM EDT - 3 months ago

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Apr 22, 2025, 7:00 AM EDT - 4 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Apr 9, 2025, 7:00 AM EDT - 4 months ago

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Feb 27, 2025, 2:48 PM EST - 6 months ago

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 6 months ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Jan 30, 2025, 7:00 AM EST - 7 months ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Jan 14, 2025, 7:00 AM EST - 7 months ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Jan 7, 2025, 7:00 AM EST - 8 months ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Dec 7, 2024, 1:07 AM EST - 9 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Nov 26, 2024, 7:00 AM EST - 9 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Nov 5, 2024, 7:00 AM EST - 10 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Nov 3, 2024, 4:11 PM EST - 10 months ago

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Oct 24, 2024, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Oct 23, 2024, 7:15 AM EDT - 10 months ago

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Oct 23, 2024, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Oct 9, 2024, 7:00 AM EDT - 11 months ago

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

Oct 6, 2024, 2:58 PM EDT - 11 months ago

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Sep 25, 2024, 7:00 AM EDT - 11 months ago

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Aug 21, 2024, 11:15 AM EDT - 1 year ago

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 19, 2024, 10:45 PM EDT - 1 year ago

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Aug 10, 2024, 11:23 AM EDT - 1 year ago

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Jul 16, 2024, 4:58 AM EDT - 1 year ago

Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating

Jul 9, 2024, 10:55 AM EDT - 1 year ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

Jul 8, 2024, 4:05 PM EDT - 1 year ago

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

d_risk Aug. 12 at 1:01 AM

0 · Reply

OpenOutcrier Aug. 11 at 12:59 PM

$KYMR (-6.5% pre) Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update https://ooc.bz/l/73463

0 · Reply

mikesterz7 Aug. 11 at 11:37 AM

$KYMR Kymera reported second quarter EPS of $-0.95, $0.12 worse than the analyst estimate of $-0.83. Revenue for the quarter came in at $11.48M versus the consensus estimate of $20M.

1 · Reply

justiceforb_85 Aug. 7 at 10:27 PM

$KYMR trying to understand why KT-474 development discontinued when that's where they presented good preliminary data? Why do they think KT-485 is superior?

0 · Reply

BioTechHealthX Aug. 6 at 4:39 PM

0 · Reply

Tumble51 Aug. 6 at 1:08 PM

$CADL Tells you something $KYMR has nothing to do, BUT is at $44 TAK is without credibility…clearly ! Under valued , no !

0 · Reply

Tumble51 Jul. 25 at 1:40 PM

$CADL Wall Street thinks more of $KYMR with NO PHASE 1 completed than they do of TAK , hahahaha $45 …no phase 1, done ..no ph2 or ph3 Read the truth and weep

1 · Reply

ZacksResearch Jul. 18 at 6:03 PM

0 · Reply

dka79 Jul. 18 at 5:22 PM

$KYMR blackrock is 5% share holder now check filing

0 · Reply

ZacksResearch Jul. 18 at 1:08 PM

1 · Reply

TipRanks Jul. 8 at 10:07 AM

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow https://www.tipranks.com/news/article/morgan-stanley-puts-these-2-stocks-on-its-buy-list-heres-why-you-should-follow $PRMB $KYMR

0 · Reply

JarvisFlow Jul. 7 at 1:00 PM

B. Riley Securities updates rating for Kymera Therapeutics ( $KYMR ) to Neutral, target set at 36 → 41.

0 · Reply

JarvisFlow Jul. 7 at 1:00 PM

B. Riley Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Neutral with a target price of 41 → 38.

0 · Reply

JarvisFlow Jul. 7 at 10:30 AM

JP Morgan has updated their rating for Kymera Therapeutics ( $KYMR ) to Overweight with a price target of 57.

0 · Reply

Grouphome Jul. 3 at 1:58 PM

$KYMR yep

1 · Reply

DonCorleone77 Jun. 29 at 9:50 PM

$KYMR $SNY Kymera Therapeutics price target raised to $54 from $51 at BofA BofA raised the firm's price target on Kymera Therapeutics (KYMR) to $54 from $51 and keeps a Buy rating on the shares. The company announced that its partner Sanofi (SNY) decided to advance KT-485, an oral IRAK4 degrader, into the clinic and discontinue development of KT-474, the analyst tells investors in a research note. The firm says that while the KT-474 update will set back the program by several years, the update reinforces Kymera and Sanofi's commitment to developing the best possible IRAK4 degrader. It remains "encouraged" by Kymera's "strong" business development capabilities to establish collaborations with large pharma for several assets in its pipeline.

0 · Reply

TaxiBiotech_ Jun. 29 at 4:58 PM

$KYMR KYMERA Updates its pipeline for IRAK4 degrader: Phase 2 KT-474 is discontinued. They’re now trying a new degrader: KT-485. Old pipeline vs updated:

0 · Reply

TaxiBiotech_ Jun. 29 at 4:53 PM

$KYMR Kymera Therapeutics $KYMR announces a $250.8M public offering (5M shares + 655K pre-funded warrants), with an option to purchase an additional 855K shares. 💵 Offering price: $44.00 📅 Expected closing date: June 30, 2025 📌 Shares outstanding: 65M (Est. fully diluted~80M) 🎯 Use of proceeds: to fund its pipeline of oral protein degraders for immunological diseases.

0 · Reply

DonCorleone77 Jun. 27 at 10:20 AM

$KYMR Kymera Therapeutics 5.043M share Spot Secondary priced at $44.00 Morgan Stanley, JPMorgan, Jefferies, TD Securities and Leerink acted as joint book running managers for the offering.

0 · Reply

ZacksResearch Jun. 26 at 7:15 PM

$KYMR drops on Sanofi exit — but here's the bullish twist 📉➡️📈 Sanofi pulled the plug on KT-474, hitting shares, but the new Gilead oncology collaboration signals fresh upside potential. Full breakdown of the double-edged update here 👉 https://www.zacks.com/stock/news/2554322/kymr-collaborates-with-gild-stock-down-on-sanofi-deal-update?cid=sm-stocktwits-2-2554322-body-262&ADID=SYND_STOCKTWITS_TWEET_2_2554322_BODY_262

0 · Reply

ZacksResearch Jun. 26 at 12:47 PM

$KYMR slips as Sanofi drops KT-474 development. ⚠️ Despite a promising deal with $GILD and a 15.5% YTD gain, the stock sees red due to Sanofi's decision not to advance KT-474, impacting potential milestone payments. 📉 Discover the full story here 👉 https://www.zacks.com/commentary/2554322/kymr-collaborates-with-gild-stock-down-on-sanofi-deal-update?cid=sm-stocktwits-2-2554322-body-156&ADID=SYND_STOCKTWITS_TWEET_2_2554322_BODY_156

0 · Reply

JarvisFlow Jun. 26 at 12:30 PM

HC Wainwright & Co. has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 54 → 60.

0 · Reply

Market Cap	3.15B
Revenue (ttm)	47.07M
Net Income (ttm)	-223.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-475.59%
Debt to Equity Ratio	0.00

Volume	508,200
Avg Vol	717,896
Day's Range	N/A - N/A
Shares Out	71.50M
Stochastic %K	94%
Beta	2.18
Analysts	Strong Sell
Price Target	$60.60